Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson's Disease

• Main Authors: Akiko Nakatsuka (Author), Masahiro Nagai (Author), Hayato Yabe (Author), Noriko Nishikawa (Author), Takuo Nomura (Author), Hiroyoko Moritoyo (Author), Takashi Moritoyo (Author), Masahiro Nomoto (Author)
• Format: Book
• Published: Elsevier, 2006-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract.: Cabergoline is used in the treatment of Parkinson's disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concent...